Magnesium Sulfate Ariti (Magnesium Sulfate)

Magnesium sulfate delivers magnesium ions that act as cofactors for many enzymes, compete with calcium at voltage‑gated channels, cause vasodilation, and stabilise excitable membranes, which together help regulate neuromuscular transmission, cardiac rhythm and vascular tone.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, serum magnesium level, renal function and other clinical factors. No standard dose is provided here.

Pregnancy safety is classified as unknown; the drug is used in obstetric emergencies such as eclampsia when benefits outweigh potential risks. Limited data are available for breastfeeding, so clinicians should evaluate the risk‑benefit ratio for each patient.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Unlike potassium or calcium salts, magnesium sulfate provides magnesium ions that uniquely act as a calcium antagonist and vasodilator. It is preferred for conditions such as eclampsia and torsades de pointes where magnesium’s specific electrophysiological effects are essential, whereas other electrolytes do not address these indications.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Maintaining the cold‑chain preserves stability and potency until the time of use.

Magnesium Sulfate Ariti is given by intravenous injection. The infusion rate and concentration are set by the prescriber, and administration is typically performed in a monitored clinical setting with cardiac and respiratory monitoring.

Serious risks include respiratory depression, severe hypotension, hypermagnesemia leading to cardiac arrest, life‑threatening arrhythmias, and rare anaphylactoid reactions. Prompt recognition and supportive measures are essential if these events occur.

Patients with known hypersensitivity to magnesium sulfate, severe renal failure without dose adjustment, or those receiving incompatible calcium‑containing solutions should not receive the product. Clinicians must also evaluate contraindications on a case‑by‑case basis.